IMMUcan

IMMUcan (Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts) is an @IHIEurope (#IMI2) project proposing an inclusive immuno-oncology platform.

[IMMUcan @IMMUcan]

Hello from Brussels! 🇧🇪 From Oct 28-30, the Scientific Advisory Board and Committee of IMMUcan met at @EORTC headquarters. We engaged in meaningful discussions on our progress and explored future research directions. Exciting times ahead!

[IMMUcan @IMMUcan]

In honour of #BreastCancerAwareness Month, we’re proud to share progress in our work breast cancer work stream. The ImmuneLandscape Laboratory map tumour microenvironments, providing essential data for personalising cancer treatments.

[IMMUcan @IMMUcan]

At the end of September, IMMUcan was featured at #UroCCR’s Scientific Days! 👏 Dr. Marie Morfouace  shared project #progress, while Dr.Jane Merlevede  & Dr. Gaëlle Margue focused on #renal cancer. Thank you for the chance to share and collaborate!

[IMMUcan @IMMUcan]

IMMUcan #recruitment complete! 🚀We’ve wrapped up patient recruitment and are prepping samples for lab analysis. Ready to dive into data from 1450-1500 SPECTA patients soon! Huge thanks to our team & participants. Exciting #discoveries await!

[IMMUcan @IMMUcan]

📢IMMUcan at #ESMO24. Andrea Joaquin Garcia is presenting her latest #research on triple-negative breast cancer (#TNBC). 🧬These insights indicate potential for personalised therapies in TNBC through spatial analysis.

[IMMUcan @IMMUcan]

Andrea Joaquín García will represent IMMUcan at the ESMO Congress 2024! Andrea's poster presentation on Sep 16th will highlight insights into triple-negative breast cancer (TNBC). Engaging at #ESMO24 helps us drive dialogue & improve patient outcomes.

[IMMUcan @IMMUcan]

Exciting September for IMMUcan! Our research will be featured at 4 prestigious events, with Dr Ewa Szczurek and her team presenting the cutting-edge models FACTM, Cellohood, and Spacelet, advancing multi-modal data integration & spatial biology.

[IMMUcan @IMMUcan]

IMMUcan seeks to identify #biomarkers and mechanisms that can inform better, personalised treatment strategies for #cancer patients. Learn more about the work we do: https://t.co/8YSZDYZjB7

[IMMUcan @IMMUcan]

We are thrilled to announce that we have reached 2000 #patients enrolled, making IMMUcan the largest #immuno-profiling effort in Europe! This is a huge step forward in advancing #cancer care: https://t.co/8YSZDYZjB7

[IMMUcan @IMMUcan]

The future of #cancer care is personalised! IMMUcan uses detailed molecular and cellular profiling to understand why some #patients respond to treatments while others don't. Learn more: https://t.co/HPSJZBIJMc

[IMMUcan @IMMUcan]

Did you know that over 1800 patients’ #data has been analysed by the IMMUcan teams? Our research aims to enhance cancer #immunology understanding and improve #immunotherapy treatments. Clinicians, researchers, sponsors, and patients can learn more here: https://t.co/4I8c7UvjId

[IMMUcan @IMMUcan]

We welcome Novigenix to our consortium! Powered by #AI and next-generation #RNA sequencing, the Novigenix’ LITOseek platform will enhance the immune profiling capabilities of IMMUcan. We aim to bridge the gap between research and clinical application. https://t.co/QsBdU2oO0O

[IMMUcan @IMMUcan]

Huge news! Study by Amelie Franken & team featured on the cover of Immunity by Cell Press! The research reveals key #immune mechanisms in #HNSCC patients. Read more: https://t.co/Anj3H4iKlT

[IMMUcan @IMMUcan]

That’s a wrap for the IMMUcan general assembly! Over the past two days we went through updates from partners & explored future plans. More insights from the research done in the project will follow!

[IMMUcan @IMMUcan]

💬 "Why do some #patients respond to cancer treatments, while others don't?"

IMMUcan studies the #TME to gain a deeper understanding of how the immune system and cancer cells interact at the molecular and cellular level.

➡ Go to https://t.co/fahnU3bEhC to learn more!

[IMMUcan @IMMUcan]

What is the story behind @IMMUcan? We are happy to explain! 📽

Watch the video to understand more about the ins and outs of the rationale behind IMMUcan.

How to join the project?
Go to https://t.co/fahnU3bEhC to learn all about it!

[IMMUcan @IMMUcan]

It’s been two months since we joined #ESMOIO2023!

We proudly presented the latest @IMMUcan #cancerresearch.

But what exactly did we bring to the table during those days in early December 2023? Let’s look back!

This week, we highlight Daniel Schulz and team!

[IMMUcan @IMMUcan]

We love working together with our #partners within @IMMUcan!

Today, we highlight our collaboration with @ClinUnivStLuc. Why is this partnership important? Dr. Philippe Stevens, PhD candidate, explains.

Curious to learn more about the project? Go to https://t.co/fahnU3bEhC

[IMMUcan @IMMUcan]

🔍 Reflecting on #ESMOImmuno23!

🗓️Last week, our IMMUcan team showcased seven poster presentations, unveiling the insights gained from IMMUcan so far.

Missed the congress? No worries! Stay tuned for insights and impressions in the coming weeks.

[IMMUcan @IMMUcan]

🎉Wrapping up an inspiring #ESMOImmuno23!

Our team successfully presented the latest IMMUcan research, fostering valuable collaborations with fellow researchers.

Tune in to our IMMUcan channels in the next few days for more insight on the conference!